biologic

Zenpep

pancrelipase

Loss of exclusivityJune 2023projected — 12-year biologic exclusivity estimate
CompanyAimmune Therapeutics, Inc.

Drug detail

Brand nameZenpep
Active ingredientpancrelipase
Strength3,000USP UNITS; 10,000USP UNITS; 14,000USP UNITS
Dosage formCapsule, Delayed Release
RouteOral
ModalityBiologic
FDA approvalJune 2011
Marketing statusRx

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Zenpep patent cliff — loss of exclusivity June 2023 | CliffBio